T 0737/20 of 18.10.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T073720.20231018
- Date of decision
- 18 October 2023
- Case number
- T 0737/20
- Petition for review of
- -
- Application number
- 11162667.7
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on EPC2000 Art 113
- Application title
- Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway
- Applicant name
- Dana-Farber Cancer Institute, Inc.
The Brigham and Women's Hospital, Inc.
Emory University
President and Fellows of Harvard College - Opponent name
- Sanofi
Regeneron Pharmaceuticals, Inc.
Janssen Sciences Ireland UC - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 113European Patent Convention Art 56European Patent Convention R 106Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 012(2)Rules of procedure of the Boards of Appeal 2020 Art 023
- Keywords
- Remittal - (no)
Right to be heard - violation (no)
Obligation to raise objections - objection dismissed
Inventive step - (no) - Catchword
- Right to be heard: see points 16 and 17 of the Reasons
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.